
OUR SCIENCE | R&D Innovative medicines in the pipeline Only 5 % of rare diseases have approved medicines. The need for innovative treatments is, therefore, high. A strong pipeline and expanded access are key elements of our commitment to patients. View pipeline RESULTS CENTRE Q4 and FY 2025 report Sobi published its Q4 and FY 2025 report on 5 February 2026.ReportPresentationWebcastInvitationAide memoire Financial reports MEDIA | PRESS RELEASES Press releases 5 February, 2026 08:00 Sobi Q4 and FY 2025 report: Closing the year with significant growth and strategic progress 3 February, 2026 09:15 Sobi to Showcase Scientific advances and Commitment to the Haemophilia community at EAHAD 2026 Learn more